Baseline characteristics and complications in 1723 patients eligible for thrombolytic treatment, stratified by thrombolytic treatment and arrival time
| No thrombolysis (n=343) | Thrombolysis (n=1380) | Arrival ≤6 h (n=1549) | Arrival >6 h (n=176) | |
|---|---|---|---|---|
| Data are n (%) for categorical variables and median (interquartile range) for continuous variables. | ||||
| *p<0.05, **p<0.01, ***p<0.001. | ||||
| CK, creatine kinase; VF, ventricular fibrillation. | ||||
| Age (years) | 66 (58 to 73) | 61 (53 to 70)*** | 62 (53 to 71) | 66 (58 to 72)** |
| Male sex | 233 (67.9) | 1038 (75.2)** | 1149 (74.2) | 124 (70.5) |
| Risk factors | ||||
| Hypertension | 121 (35.8) | 443 (32.4) | 513 (33.4) | 51 (29.7) |
| Diabetes | 76 (22.4) | 304 (22.1) | 343 (22.2) | 37 (21.1) |
| Current smoking | 166 (49.7) | 634 (46.5) | 714 (46.8) | 87 (50.3) |
| Emergency aspirin | 221 (14.5) | 1302 (85.5)*** | 1365 (91.0) | 159 (93.5) |
| Infarct characteristics | ||||
| Anterior infarction | 149 (44.2) | 617 (45.8) | 680 (44.9) | 86 (49.7) |
| Q wave infarction | 268 (78.8) | 1080 (78.7) | 1211 (78.7) | 139 (79.4) |
| Previous infarction | 98 (28.6) | 215 (15.6)*** | 282 (18.3) | 31 (17.8) |
| Peak CK (IU/l) | 1012 (510 to 1892) | 1169 (496 to 2038) | 1162 (498 to 2030) | 1022 (503 to 1812) |
| Complications | ||||
| VF | 51 (15.0) | 92 (6.7)*** | 137 (8.9) | 6 (3.4)** |
| Heart failure | 128 (37.5) | 370 (26.9)** | 437 (28.3) | 62 (35.2) |
| Hospital death | 67 (21.9) | 106 (9.1)*** | 180 (11.6) | 21 (11.9) |